Experimental Human Pneumococcal Challenge With SPN3 (Challenge3)
Serotype 3 Experimental Human Pneumococcal Challenge; Dose Ranging and Reproducibility in a Healthy Volunteer Population
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past decade with no serious side effects and now want to test the model using a different strain of the bacteria that is commonly found in the community, SPN3.
The aim of this study is to determine how much pneumococcus is needed to achieve nasal colonisation and how long the bacteria live in the nose for before natural immune responses eradicate them. By doing this, Investigators will then be able to test how well future vaccines prevent colonisation with pneumococcus. Investigators want to learn more about how the immune system responds to nasal colonisation with pneumococcus, again to help with development of new vaccines.
Study Overview
Status
Detailed Description
In this study, investigators propose to determine the optimal dose and isolate of SPN3 to establish colonisation in the human nasopharynx, as well as improving knowledge of immune responses to SPN3 colonisation. The results from this study will be used to inform development of improved SPN3 vaccines and to inform design of future pneumococcal vaccine RCTs.
To increase the relevance of the EHPC model and its use for assessing future vaccines such as V114, investigators are proposing here to set up an EHPC model with carefully selected non-proprietary SPN3 strains. Investigators will conduct a safety and dose-ranging study to determine the optimum SPN3 strain and dose for colonisation acquisition and confirm the dose in a subsequent larger cohort in a reproducibility study and will study mucosal and systemic immune responses to this serotype and their association with protection against colonisation acquisition and clearance.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Liverpool, United Kingdom, L7 8XZ
- Liverpool School of Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:• Healthy young adults aged 18-50 years (inclusive). This age range minimises the risk of invasive pneumococcal infection and allows comparison with previously published experimental work done by our group.
- Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement, enabling valid consent to be given.
- Access to their own mobile telephone - to ensure safety and timely communication.
- Capacity to give informed consent.
Exclusion Criteria:
o Currently involved in another study unless observational or non-interventional, excluding the EHPC bronchoscopy study (at the discretion of the study team). This is to ensure no harm comes to the participants through over-sampling.
- Participant in any previous EHPC trial in past year
- Participant in previous EHPC trial inoculated with SPN3 in the last 3 years
Participant in EHPC Pneumo 2 trial
- Vaccination: Previous pneumococcal vaccination PPV23 or PCV13 (routine in babies born in the UK since 2005) or PCV10. This can be self-reported or confirmed from GP questionnaire (GPQ) if deemed necessary at clinician discretion.
- Allergy: to penicillin/amoxicillin
- Health history (self-reported or confirmed by GPQ or medical summary if felt to be necessary at clinician discretion):
- Chronic ill health including immunosuppressive history, diabetes, asthma (on regular medication), recurrent otitis media or other respiratory disease.
- Medication that may affect the immune system e.g., steroids, inflammation altering or disease-modifying anti-rheumatoid drugs.
- Long term use of antibiotics for chronic infection.
- Major pneumococcal illness requiring hospitalisation in the last 10 years.
- Other conditions considered by the clinical team as a concern for participant safety or integrity of the study
Significant mental health problems (uncontrolled condition or requiring previous admission to a psychiatric unit) that would impair ability to participate
• Direct caring role or close contact with individuals at higher risk of infection during the inoculation period if personal protective equipment (PPE) not worn:
- Children under 5 years age
- Adults with chronic ill health or immunosuppression
Hospital patients
• Smoker:
- Current or ex-smoker (daily cigarettes, daily e-cigarettes/vaping and daily smoking of recreational drugs) in the last 6 months. Participants who smoke <5 cigarettes per week may be included.
Previous significant smoking history (>20 cigarettes per day for 20 years or equivalent [>20 pack years]).
• Biologically female participants of child-bearing potential (WOCBP) who are:
- Currently pregnant/lactating
- Intending on becoming pregnant during the study
Not deemed to have effective birth control
• History of or current drug or alcohol abuse:
- Men should not drink >3 units/day regularly
Women should not drink >2 units/day regularly
- Overseas travel planned in follow up period of study visits
- Natural SPN 3 colonisation in baseline nasal wash - if a participant is colonised with non-SPN3 pneumococcus, they can be included as part of exploratory analyses, but would not be included in the primary analysis
- STOP criteria - participants who meet STOP criteria at time of screening (Table 3) 6.3 Temporary Exclusion Criteria
- Ongoing COVID-19 symptoms (fever, cough, shortness of breath, anosmia or ageusia) or confirmed current COVID-19 infection. Participants with resolved COVID-19 after their UKHSA determined isolation period has ended can be included.
- Current/acute illness within 14 days prior to inoculation if COVID-19 negative
- Positive COVID-19 swab whether symptomatic or asymptomatic within 10 days of inoculation
- Currently isolating following exposure to COVID-19 as per UKHSA guidance
- Antibiotic use within 28 days of inoculation.
- Participants who have been temporarily excluded at screening may be re-screened at a later date to assess their eligibility at this time for inclusion into the study. At this point, the participant would be re-consented if their initial written consent was given >4 months prior to this date.
- Vaccination 21 days prior to inoculation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MLW-10V, 10000 CFU/ml
Malawi isolate, low dose
|
Dose-ranging study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
|
Experimental: MLW-10V, 20000 CFU/ml
Malawi isolate, intermediate dose
|
Dose-ranging study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
|
Experimental: MLW-10V, 80000 CFU/ml
Malawi isolate, higher dose
|
Dose-ranging study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
|
Experimental: LIV014-S3, 10000 CFU/ml
Liverpool isolate, low dose
|
Dose-ranging and reproducibility study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
|
Experimental: LIV014-S3, 20000 CFU/ml
Liverpool isolate, intermediate dose
|
Dose-ranging and reproducibility study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
|
Experimental: LIV014-S3, 80000 CFU/ml
Liverpool isolate, higher dose (includes dose-ranging and reproducibility study participants, since the reproducibility study only included this isolate and dose)
|
Dose-ranging and reproducibility study of SPN3 inoculation AND targeted booster inoculation at day-14, where prime inoculation fails to lead to experimental colonisation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To Determine the Optimal SPN3 Dose and Isolate to Establish Colonisation of the Nasopharynx in Healthy Adults
Time Frame: From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
The proportion of participants with experimental SPN3 colonisation of the nasopharynx, determined by SPN3 presence in classical microbiological culture in at least one nasal wash (NW) sample, at any time point following one or two inoculations (combined and individually).
This will be assessed for each isolate and dose separately.
|
From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To Determine the Density of Experimental SPN3 Colonisation of the Nasopharynx.
Time Frame: From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
The bacterial density of experimental SPN3 colonisation of the nasopharynx in NW, at each and any time point following one or two inoculations (combined and individually), determined by classical microbiological culture, assessed for each isolate and dose separately.
The number of participants analysed includes only the participants who developed SPN3 colonisation in each arm/group, rather than the total number of participants inoculated.
|
From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
|
To Determine the Duration of Experimental SPN3 Colonisation of the Nasopharynx.
Time Frame: From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
The duration of experimental SPN3 colonisation of nasopharynx determined by the last NW sample following one or two inoculations in which SPN3 is detected by classical microbiological culture, assessed for each isolate and dose separately.
Note - number of participants analyzed in this outcome measure is different (and lower) than overall number of participants in participant flow section, because duration of colonisation can only apply to participants who developed experimental colonisation from at least one timepoint post-inoculation.
|
From inoculation (day 0) to the final visit for each participant (28 days post-inoculation)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrea Collins, MBChB, PhD, Senior Clinical Lecturer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Streptococcus Pneumonia
-
Universidad de la SabanaRecruitingCommunity-acquired Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae Pneumonia | Streptococcus Pneumoniae Infection InvasiveColombia
-
Medical Corps, Israel Defense ForceCompletedGroup A Streptococcus | Streptococcus Pneumonia | Carriage
-
Tam Anh Research InstitutePfizerCompletedStreptococcus PneumoniaVietnam
-
PfizerCompleted
-
University of OxfordPfizerUnknownStreptococcal Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae, Invasive DiseaseUnited Kingdom
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
-
Liverpool School of Tropical MedicinePfizerRecruitingStreptococcus PneumoniaUnited Kingdom
-
University of Colorado, DenverPfizerCompletedCommunity-acquired Pneumonia | Streptococcus Pneumoniae InfectionGuatemala
-
Fosun Adgenvax Biopharmaceutical Co.,Ltd.Active, not recruitingStreptococcus Pneumoniae InfectionChina
-
UMC UtrechtNetherlands: Ministry of Health, Welfare and Sports; Netherlands Vaccine InstituteCompletedStreptococcus Pneumoniae Infection